Search

everythinglearnresearchcommunity

for

Search:↓

Sonirid Duo effectively treats benign prostatic hyperplasia.

Combination therapy with Finasteride is more effective than alpha-blocker alone for BPH symptoms in small prostate volume.

Using tamsulosin and finasteride together for benign prostatic syndrome has increased and shows improvement in symptoms, but more reliable comparisons are needed.

The journal retracted an article due to inaccurate statistics and asked the authors to revise and resubmit it.

Finasteride and dutasteride are equally effective and safe for treating benign prostatic hyperplasia.

Blood tests for tumor cells could improve prostate cancer diagnosis and treatment; hair loss severity linked to a gene affecting prostate conditions.

A new method using a Foley catheter on a ureteroscope makes difficult urethral catheterization easier and more effective.

A reliable method was created to measure tamsulosin in human blood.

Estradiol and castration reduced prostate cancer development in rats when applied at early stages, but were ineffective after cancer was established.

Combining α1-blockers with 5α-reductase inhibitors improves urinary symptoms in men.

Using testosterone-stimulated weanling rats can effectively replace castrated rats for anti-androgen testing, reducing animal stress.

Dutasteride is slightly better than finasteride for treating BPH but has fewer sexual side effects.

New treatments are making advanced prostate cancer management more complex but also more hopeful.

Finasteride may cause breast enlargement, low testosterone a risk factor.

Ursolic acid can shrink the prostate and lower a hormone linked to prostate growth in rats.

5-alpha-reductase inhibitors lower PSA density but higher PSA density indicates disease progression.

Taking 5-Alpha Reductase Inhibitors before bladder removal surgery might make high-grade bladder tumors less aggressive.

The method accurately measures testosterone metabolites with high sensitivity and low environmental impact.

Researchers developed a quick and accurate method to measure hormones in urine, confirming a baldness treatment's effectiveness without altering hormone levels.

Patients follow treatment well, but many change medicines; good information helps compliance.

Evidence-based urology improved treatment and quality of life for conditions like BPH by shifting from surgery to effective medications like finasteride and dutasteride.

The BJUI supports clinical trials as key for unbiased medical evidence and works to enhance their design, reporting, and discussion.

Long-term medication for enlarged prostate might not clearly affect the timing or outcomes of later surgery.

Higher SRD5A2 expression predicts better response to finasteride in treating urinary symptoms.

2007 research improved understanding of prostate cancer risk, diagnosis, and treatment, but also showed the need for personalized treatment and further study on certain therapies' risks.

The conclusion is that tritium-labeled testosterone metabolites can be made and are better converted into dihydrotestosterone in skin cells than in prostate tissue.

PRP treatment improves chronic tendinopathy, and imaging biomarkers can track tendon changes.

Testosterone replacement therapy, especially intramuscular, raises PSA levels, but no overall link between PSA and testosterone was found except in non-BPH patients.

Combination therapy improves urinary flow and reduces residual urine, but needs better stent design.